Voyager Therapeutics, Inc.
NASDAQ:VYGRBiotechnology
+$0.09 today
- Market cap
- $103.92M
- Beta
- 1.25
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$1.96
Volume 0.84M
Average 0.54M
VYGR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Voyager Therapeutics, Inc.NASDAQ: VYGR
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $27.94M (cash outflow) fell 9.9% year over year, behind the +37.7% change in trailing-twelve-month net income. Sequentially, it rose 1.9% from the prior quarter. Over 3 fiscal years it compounded at +37.1% a year.
Context
- Net income amounted to 296.5% of revenue in FY2025, up 215.3 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$89.97M (-24.9%) for the fiscal year ending Dec 2026, a slowdown from the +84.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$27.94M+1.9% QoQ
- Last fiscal yearDec 2025
- -$119.72M+84.2% YoY
- LTMMar 2026
- -$116.64M+37.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.9% | -10.4% | -0.5 pp |
| 1 year | +84.2% | -24.9% | -109.0 pp |
| 3-year CAGR | +37.1% | -12.2% | -49.3 pp |
| 5-year CAGR | -9.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (119.72M) USD
- Year-over-year change
- -84.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (119.72M) | -84.2% |
| FY2024 | 2024-12-31 | (65M) | -149.1% |
| FY2023 | 2023-12-31 | 132.33M | +385.1% |
| FY2022 | 2022-12-31 | (46.41M) | +34.8% |
| FY2021 | 2021-12-31 | (71.2M) | — |
Net Income vs competitors
How VYGR compares with its peers on the latest reported figures
- VYGR's LTM Mar 2026 net income of $116.64M is the 5th largest of the 11 companies compared; the peer median is $89.66M.
- Its year-over-year change of +37.7% is the 2nd highest of 11, against a peer median of -0.8%.
- Net income amounts to 319.6% of revenue for VYGR, versus a peer median of 381.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $239.55M | +441.4% | — | 110.0% | |
| LTM Mar 2026 | $173.76M | -31.1% | -16.9% | — | |
| LTM Mar 2026 | $169.52M | +21.5% | +11.0% | — | |
| LTM Mar 2026 | $166.12M | -770.3% | +15.0% | 2895.1% | |
| LTM Mar 2026 | $116.64M | +37.7% | +37.1% | 319.6% | |
| LTM Mar 2026 | $97.59M | +25.7% | +50.6% | 4840.8% | |
| LTM Mar 2026 | $81.74M | -14.2% | -13.0% | 589.8% | |
| LTM Mar 2026 | $78.67M | +15.4% | — | 173.5% | |
| LTM Mar 2026 | $61.98M | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $51.99M | +12.6% | +8.9% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $43.51M | -23.8% | +18.7% | — |
| Peer median (excluding VYGR) | $89.66M | -0.8% | +9.9% | 381.6% | |
Competitors are the stored peer set for VYGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.2M) | (46.41M) | 132.33M | (65M) | (119.72M) |
| Depreciation & Amortization | 5.17M | 6.19M | 4.44M | 4.73M | 4.06M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.32M | 9.34M | 11.15M | 14.79M | 14.79M |
| Change in Working Capital | 3.29M | 20.47M | (66.56M) | 34.86M | (28.76M) |
| Accounts Receivables | 7.28M | 475K | (83.23M) | 81.31M | 268K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (60K) | 1.99M | (962K) | 2.39M | 1.02M |
| Other Working Capital | (3.93M) | 18M | 17.64M | (48.84M) | (30.05M) |
| Other Non-Cash Items | (2.11M) | (2.11M) | (3.45M) | (4.68M) | (2.83M) |
| Operating Cash Flow | (53.53M) | (12.51M) | 77.92M | (15.31M) | (132.47M) |
| Capital Expenditures | (1.61M) | (2.49M) | (3.26M) | (3.52M) | (2.6M) |
| Acquisitions (Net) | 0 | 0 | 138.39M | 0 | 0 |
| Purchases of Investments | (15.12M) | (54.85M) | (223.97M) | (465.69M) | (133.93M) |
| Sales of Investments | 82.63M | 50M | 85.58M | 374.35M | 261.97M |
| Other Investing Activities | 0 | 0 | (138.39M) | 0 | 0 |
| Investing Cash Flow | 65.91M | (7.34M) | (141.64M) | (94.86M) | 125.45M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 612K | 1.11M | 33.65M | 114.02M | 816K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 612K | 1.11M | 33.65M | 114.02M | 816K |
| Effect of Forex Changes | 0 | 264K | 0 | 0 | 0 |
| Net Change in Cash | 12.99M | (18.47M) | (30.08M) | 3.85M | (6.21M) |
| Free Cash Flow | (55.13M) | (15M) | 74.66M | (18.83M) | (135.06M) |
Voyager Therapeutics, Inc.
NASDAQ:VYGR
Intrinsic Alpha fair value
Locked
Current Price
$1.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.